{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:32:33Z","timestamp":1787963553115,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003669","name":"Korea Centers for Disease Control & Prevention","doi-asserted-by":"publisher","award":["2015-177"],"award-info":[{"award-number":["2015-177"]}],"id":[{"id":"10.13039\/501100003669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-018-3053-1","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T09:02:43Z","timestamp":1547629363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II\/III, multicenter, randomized, open-label clinical trial"],"prefix":"10.1186","volume":"20","author":[{"given":"Myungsun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongha","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deog Kyeom","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Sun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Jung","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doosoo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taehoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Heon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Sang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Seuk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Yee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Wook","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Woo","family":"Jhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ae","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joong Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeksun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jae","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ran","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokyung","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Jeong","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yeon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Nae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Joon","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,16]]},"reference":[{"key":"3053_CR1","volume-title":"Global tuberculosis report 2014","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Global tuberculosis report 2014. 2014"},{"key":"3053_CR2","unstructured":"World Health Organization. Global tuberculosis report 2017. 2017"},{"key":"3053_CR3","first-page":"44","volume-title":"Annual report on the notified tuberculosis in Korea 2016","author":"Korea Centers for Disease Control and Prevention","year":"2016","unstructured":"Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis in Korea 2016. Cheongju: Korea Centers for Disease Control and Prevention; 2016. p. 44."},{"key":"3053_CR4","doi-asserted-by":"publisher","unstructured":"Jeon D. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update: applicability in South Korea. Tuberc Respir Dis. 2017;80(4):336\u201343. \n                    https:\/\/doi.org\/10.4046\/trd.2017.0049\n                    \n                   Epub 2017 Sep 1.","DOI":"10.4046\/trd.2017.0049"},{"key":"3053_CR5","volume-title":"Treatment guidelines for drug-resistant tuberculosis","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Treatment guidelines for drug-resistant tuberculosis. 2016"},{"issue":"2","key":"3053_CR6","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1097\/01.mjt.0000433951.09030.5a.","volume":"23","author":"S Wu","year":"2016","unstructured":"Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, Zhan S. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Ther. 2016;23(2):e521\u201330. \n                    https:\/\/doi.org\/10.1097\/01.mjt.0000433951.09030.5a.","journal-title":"Am J Ther"},{"key":"3053_CR7","doi-asserted-by":"publisher","first-page":"961","DOI":"10.5588\/ijtld.11.0574","volume":"167","author":"MW Carroll","year":"2012","unstructured":"Carroll MW, Lee M, Cai Y, et al. Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort. Int J Tuberc Lung Dis. 2012;167:961\u20136.","journal-title":"Int J Tuberc Lung Dis."},{"key":"3053_CR8","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1183\/09031936.00022912","volume":"40","author":"G Sotgiu","year":"2012","unstructured":"Sotgiu G, Centis R, D\u2019Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR- TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40:1430\u201342. \n                    https:\/\/doi.org\/10.1183\/09031936.00022912\n                    \n                  .","journal-title":"Eur Respir J"},{"key":"3053_CR9","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","volume":"367","author":"M Lee","year":"2012","unstructured":"Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367:1508\u201318. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1201964\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"3053_CR10","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","volume":"366","author":"MT Gler","year":"2012","unstructured":"Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151\u201360. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1112433\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"23","key":"3053_CR11","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","volume":"360","author":"AH Diacon","year":"2009","unstructured":"Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397\u2013405. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0808427\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"3053_CR12","doi-asserted-by":"publisher","unstructured":"Chang KC, Yew WW, Sotgiu G. Clinical research in the treatment of tuberculosis: current status and future prospects. Int J Tuberc Lung Dis. 2015;19(12):1417\u201327. \n                    https:\/\/doi.org\/10.5588\/ijtld.15.0216.Review.","DOI":"10.5588\/ijtld.15.0216.Review."},{"key":"3053_CR13","volume-title":"2nd ed","author":"Joint Committee for the Revision of Korean Guidelines for Tuberculosis","year":"2014","unstructured":"Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis. In: 2nd ed; 2014. \n                    http:\/\/www.lungkorea.org\/thesis\/file\/korean_guidelines_for_tuberculosis_2014.pdf\n                    \n                  ."},{"issue":"3","key":"3053_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4046\/trd.2015.78.3.168","volume":"78","author":"D Jeon","year":"2015","unstructured":"Jeon D. Medical management of drug-resistant tuberculosis. Tuberc Respir Dis (Seoul). 2015;78(3):168\u201374. \n                    https:\/\/doi.org\/10.4046\/trd.2015.78.3.168\n                    \n                   Epub 2015 Jun 30.","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"3053_CR15","unstructured":"World Health Organization. Companion handbook to the guidelines for the programmatic management of drug-resistant tuberculosis, vol. 2014. \n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/130918\/1\/9789241548809_eng.pdf"},{"issue":"5","key":"3053_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.5588\/ijtld.14.0739","volume":"19","author":"N Kwak","year":"2015","unstructured":"Kwak N, Kim HR, Yoo CG, Kim YW, Han SK, Yim JJ. Changes in treatment outcomes of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19(5):525\u201330. \n                    https:\/\/doi.org\/10.5588\/ijtld.14.0739\n                    \n                  .","journal-title":"Int J Tuberc Lung Dis."},{"issue":"3","key":"3053_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1513\/AnnalsATS.201510-690BC","volume":"13","author":"YA Kang","year":"2016","unstructured":"Kang YA, Shim TS, Koh WJ, et al. Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes. Ann Am Thorac Soc. 2016;13(3):364\u201370. \n                    https:\/\/doi.org\/10.1513\/AnnalsATS.201510-690BC\n                    \n                  .","journal-title":"Ann Am Thorac Soc"},{"key":"3053_CR18","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","volume":"182","author":"A Deun Van","year":"2010","unstructured":"Van Deun A, Maug AK, Salim MAH, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684\u201392.","journal-title":"Am J Respir Crit Care Med"},{"key":"3053_CR19","doi-asserted-by":"publisher","first-page":"1700061","DOI":"10.1183\/13993003.00061-2017","volume":"50","author":"FA Khan","year":"2017","unstructured":"Khan FA, Salim MAH, du Cros P, Casas EC, Khamraev A, Sikhondze W, Benedetti A, Bastos M, Lan Z, Jaramillo E, Falzon D, Menzies D. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J. 2017;50:1700061. \n                    https:\/\/doi.org\/10.1183\/13993003.00061-2017\n                    \n                  .","journal-title":"Eur Respir J"},{"issue":"8","key":"3053_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1164\/rccm.201606-1097LE","volume":"194","author":"C Lange","year":"2016","unstructured":"Lange C, Duarte R, Fr\u00e9chet-Jachym M, Guenther G, Guglielmetti L, Olaru I, Oliveira O, Rumetshofer R, Veziris N, Van Leth F. Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe. Am J Respir Crit Care Med. 2016;194(8):1029\u201331.","journal-title":"Am J Respir Crit Care Med"},{"key":"3053_CR21","doi-asserted-by":"publisher","unstructured":"Javaid A, Ahmad N, Khan AH, Shaheen Z. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. Eur Respir J. 2016. \n                    https:\/\/doi.org\/10.1183\/13993003.01967-2016\n                    \n                  .","DOI":"10.1183\/13993003.01967-2016"},{"key":"3053_CR22","doi-asserted-by":"publisher","first-page":"1602309","DOI":"10.1183\/13993003.02309-2016","volume":"49","author":"M Dalcolmo","year":"2017","unstructured":"Dalcolmo M, Gayoso R, Sotgiu G, D'Ambrosio L, Rocha JL, Borga L, Fandinho F, Braga JU, Sanchez DA, Dockhorn F, Centis R, Migliori GB. Resistance profile of drugs composing the \u201cshorter\u201d regimen for multidrug-resistant tuberculosis in Brazil, 2000\u20132015. Eur Respir J. 2017;49:1602309. \n                    https:\/\/doi.org\/10.1183\/13993003.02309-2016\n                    \n                  .","journal-title":"Eur Respir J"},{"key":"3053_CR23","doi-asserted-by":"publisher","first-page":"1700753","DOI":"10.1183\/13993003.00753-2017","volume":"50","author":"CBE Chee","year":"2017","unstructured":"Chee CBE, KhinMar K-W, Sng L-H, Jureen R, Cutter J, Lee VJM, Wang Y-T. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Eur Respir J. 2017;50:1700753. \n                    https:\/\/doi.org\/10.1183\/13993003.00753-2017\n                    \n                  .","journal-title":"Eur Respir J"},{"issue":"4","key":"3053_CR24","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3346\/jkms.2017.32.4.636","volume":"32","author":"JH Mok","year":"2017","unstructured":"Mok JH, Kang BH, Lee T, Lee H-K, Jang HJ, Cho YJ, Jeon D. Additional drug resistance patterns among multidrug-resistant tuberculosis patients in Korea: implications for regimen design. J Korean Med Sci. 2017;32(4):636\u201341. \n                    https:\/\/doi.org\/10.3346\/jkms.2017.32.4.636\n                    \n                  .","journal-title":"J Korean Med Sci"},{"key":"3053_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1056\/NEJMc1500286","volume":"373","author":"M Lee","year":"2015","unstructured":"Lee M, Cho S, Barry CE. Linezolid for XDR-TB \u2014 Final study outcomes. N Engl J Med. 2015;373:290\u20131. \n                    https:\/\/doi.org\/10.1056\/NEJMc1500286\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"3053_CR26","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1183\/09031936.00125812","volume":"41","author":"V Skripconoka","year":"2013","unstructured":"Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013;41:1393\u2013400. \n                    https:\/\/doi.org\/10.1183\/09031936.00125812\n                    \n                  .","journal-title":"Eur Respir J"},{"key":"3053_CR27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"AH Diacon","year":"2014","unstructured":"Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371:723\u201332. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1313865\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"3053_CR28","doi-asserted-by":"publisher","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","volume":"49","author":"SE Borisov","year":"2017","unstructured":"Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline- containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49:1700387. \n                    https:\/\/doi.org\/10.1183\/13993003.00387-2017\n                    \n                  .","journal-title":"Eur Respir J"},{"key":"3053_CR29","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","volume":"3","author":"M Matsumoto","year":"2006","unstructured":"Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLOS Med. 2006;3:e466.","journal-title":"PLOS Med"},{"key":"3053_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1128\/AAC.01691-15","volume":"60","author":"R Tasneen","year":"2016","unstructured":"Tasneen R, Betoudji F, Tyagi S, et al. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrobial Agents Chemother. 2016;60:270\u20137.","journal-title":"Antimicrobial Agents Chemother"},{"key":"3053_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.5588\/ijtld.11.0451","volume":"16","author":"H Cox","year":"2012","unstructured":"Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012;16:447\u201354.","journal-title":"Int J Tuberc Lung Dis"},{"key":"3053_CR32","doi-asserted-by":"publisher","first-page":"949","DOI":"10.5588\/ijtld.10.0616","volume":"15","author":"AH Diacon","year":"2011","unstructured":"Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011;15:949\u201354.","journal-title":"Int J Tuberc Lung Dis"},{"key":"3053_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0924-8579(00)00337-X","volume":"17","author":"JC Rodriguez","year":"2001","unstructured":"Rodriguez JC, Ruiz M, Climent A, Royo G. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents. 2001;17:229\u201331.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"3053_CR34","doi-asserted-by":"publisher","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","volume":"9","author":"SD Ahuja","year":"2012","unstructured":"Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLOS Med. 2012;9(8):e1001300 Epub 2012 Aug 28.","journal-title":"PLOS Med"},{"issue":"4","key":"3053_CR35","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S0009-9236(03)00009-2","volume":"73","author":"GJ Noel","year":"2003","unstructured":"Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73(4):292\u2013303.","journal-title":"Clin Pharmacol Ther"},{"key":"3053_CR36","unstructured":"McCune RM Jr, McDermott W, Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med. 1956;104:763\u2013802."},{"key":"3053_CR37","unstructured":"Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis. In: 3rd ed; 2017. \n                    http:\/\/tbzero.cdc.go.kr\/tbzero\/fileDown\/2015consultationguide.pdf\n                    \n                  ."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3053-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-3053-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3053-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T19:04:21Z","timestamp":1579115061000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-3053-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,16]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3053"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-3053-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,16]]},"assertion":[{"value":"6 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial received ethical approval from the Institutional Review Boards of all participating sites: Seoul National University Hospital (approval number H-1508-105-696), National Medical Center (approval number H-1602-063-002), Dankook University Hospital (approval number DKUH 2016-03-001), Pusan National University Hospital (approval number H-1602-010-053), Korea University Ansan Hospital (approval number AS16181), Samsung Medical Center (approval number SMC 2016-02-122), Asan Medical Center (approval number 2016-0316), Seoul Metropolitan Government (SMG)-Seoul National University (SNU) Boramae Medical Center (approval number 26-2016-22), Pusan National University Yangsan Hospital (approval number 04-2016-003), Severance Hospital, Yonsei University College of Medicine (approval number 4-2016-0141), Ulsan University Hospital (approval number UUH 2016-02-013), and the Catholic University of Korea Incheon St. Mary\u2019s Hospital (approval number OC16MNMS0020). Participants must provide signed and dated written informed consent prior to undergoing any study-specific procedures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"57"}}